WARREN, N.J., March 29, 2023 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company…
WARREN, N.J., March 29, 2023 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company…
PMN310 demonstrated greater selectivity for target toxic oligomers over monomers compared to other amyloid-beta-directed antibodies….
PMN310 demonstrated greater selectivity for target toxic oligomers over monomers compared to other amyloid-beta-directed antibodies….
SUNNYVALE, Calif., March 29, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular…
SUNNYVALE, Calif., March 29, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular…
Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases SAN FRANCISCO, March…
Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases SAN FRANCISCO, March…
– Phase 2b clinical trial for AB-2004 in autism irritability ongoing and enrollment anticipated to…
– Phase 2b clinical trial for AB-2004 in autism irritability ongoing and enrollment anticipated to…
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease…
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease…
VANCOUVER, British Columbia, March 29, 2023 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
VANCOUVER, British Columbia, March 29, 2023 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a…
CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a…
ARLINGTON, Mass., March 29, 2023 (GLOBE NEWSWIRE) — Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical…
ARLINGTON, Mass., March 29, 2023 (GLOBE NEWSWIRE) — Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical…
ZUG, Switzerland and BOSTON, March 29, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
ZUG, Switzerland and BOSTON, March 29, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…